| olanzapine / Generic mfg. |
2006-005346-37: A Randomized, Double-Blind, Placebo-Controlled Maintenance of Effect Study of Olanzapine in the Treatment of Disruptive Behavioral Symptoms in Children and Adolescents with Pervasive Developmental Disorders |
|
|
| | 3 | 576 | Europe | olanzapine, Tablet, Capsule*, ZYPREXA | Eli Lilly and Company Limited | children and adolescents with disruptive behavioral symptoms associated with Pervasive Developmental Disorders (PDD) | | | | |
NCT00236457: A Study Comparing the Efficacy of Long-acting Injectable Risperidone and Olanzapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder |
|
|
| Completed | 3 | 629 | US | risperidone | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia, Psychotic Disorders | | 12/02 | | |
NCT00712686: Comparative Study of Aripiprazole and Olanzapine in the Treatment of Patients With Acute Schizophrenia |
|
|
| Completed | 3 | 690 | Europe, RoW | Aripiprazole, Abilify, Olanzapine | Otsuka Pharmaceutical Development & Commercialization, Inc. | Schizophrenia | 12/03 | 12/03 | | |
NCT00077714: Trial Evaluating the Efficacy and Safety of 2 Fixed Doses of Paliperidone Extended-Release (ER) Tablets in the Treatment of Adult Patients With Schizophrenia |
|
|
| Completed | 3 | 12 | US | Paliperidone ER | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | | 01/05 | | |
NCT00078039: Trial Evaluating Three Fixed Dosages of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With Schizophrenia |
|
|
| Completed | 3 | 630 | US | Paliperidone ER | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | | 01/05 | | |
NCT00034892: CAFE Comparison of Atypicals in First Episode of Psychosis |
|
|
| Completed | 3 | | US, Canada | Olanzapine, risperidone | AstraZeneca, University of North Carolina | Schizophrenia, Psychotic Disorders, Mental Health, Mental Disorders | 03/05 | 03/05 | | |
NCT00051298: Olanzapine Versus Placebo in the Treatment of Adolescents With Schizophrenia |
|
|
| Completed | 3 | 107 | US, RoW | Olanzapine, Placebo | Eli Lilly and Company | Schizophrenia | | 04/05 | | |
NCT00083668: Trial Evaluating Three Fixed Doses of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With Schizophrenia |
|
|
| Completed | 3 | 619 | US | Paliperidone ER | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | | 05/05 | | |
NCT00485680: Olanzapine Versus Comparator in the Treatment of Bipolar Disorder |
|
|
| Completed | 3 | 140 | RoW | Olanzapine Hydrochloride, Lithium Carbonate | Eli Lilly and Company | Bipolar Disorder | | 06/05 | | |
| Completed | 3 | 700 | Europe | Aripiprazole, Abilify, Olanzapine or Quetiapine or Risperidone | Otsuka Pharmaceutical Development & Commercialization, Inc., Otsuka America Pharmaceutical | Schizophrenia | 08/05 | 08/05 | | |
NCT00091650: Olanzapine in Patients With Borderline Personality Disorder |
|
|
| Completed | 3 | 300 | US, Europe | Olanzapine, placebo | Eli Lilly and Company | Borderline Personality Disorder | | 11/05 | | |
NCT00210769: A Study of the Long-term Safety and Tolerability and the Long-term Effectiveness of Extended-release Oral Paliperidone in Patients Diagnosed With Schizophrenia |
|
|
| Completed | 3 | 203 | US | paliperidone ER Oros | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | | 12/05 | | |
NCT00088036: Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder |
|
|
| Completed | 3 | 450 | US, Europe, RoW | Olanzapine | Eli Lilly and Company | Borderline Personality Disorder | | 01/06 | | |
NCT00230828: Patient-reported Outcomes in the Treatment of Schizophrenia |
|
|
| Completed | 3 | | US | bifeprunox | Solvay Pharmaceuticals | Schizophrenia | 01/06 | | | |
NCT00211562: Adjunctive Supplementation of Antioxidants (Vitamins E + C) Plus Omega-3 Fatty Acids |
|
|
| Terminated | 3 | 20 | US | Olanzapine, Omega 3, Vitamin E+C | Augusta University, Eli Lilly and Company, Medical Service Line ABRC, US Department of Veterans Affairs | Schizophrenia | 01/06 | | | |
NCT00151424: Efficacy and Safety of Asenapine With Placebo and Olanzapine (41022)(P05947) |
|
|
| Completed | 3 | 277 | NA | asenapine, Placebo, Olanzapine | Organon and Co | Schizophrenia | 01/06 | 02/06 | | |
NCT00194064: Pilot Study Evaluating the Safety and Efficacy of Open-Label Olanzapine |
|
|
| Terminated | 3 | 18 | US | Olanzapine, Zyprexa | University Hospitals Cleveland Medical Center, Eli Lilly and Company | Bipolar Disorder | 02/06 | 02/06 | | |
NCT00650793: A 52-week, Open-label Extension Study Following a 6-week, Double-blind, Placebo- and Active- Controlled Study (R076477-SCH-303) to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia |
|
|
| Completed | 3 | 473 | US | Extended Release OROS® Paliperidone | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | | 02/06 | | |
NCT00113594: Olanzapine Treated Adolescents With Schizophrenia or Bipolar I Disorder |
|
|
| Completed | 3 | 100 | US, RoW | Olanzapine | Eli Lilly and Company | Schizophrenia, Bipolar Disorder | | 03/06 | | |
NCT00212784: Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935) |
|
|
| Completed | 3 | 1225 | NA | asenapine, Org 5222, SCH 900274, olanzapine | Organon and Co | Schizophrenia, Schizoaffective Disorder | 03/06 | 03/06 | | |
NCT00159796: 3-week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07009) |
|
|
| Completed | 3 | 489 | NA | Asenapine, Org 5222, Olanzapine, Placebo | Organon and Co, Pfizer | Bipolar Disorder | 03/06 | 04/06 | | |
NCT00156117: Efficacy and Safety of Asenapine With Placebo and Olanzapine (41021)(P05933) |
|
|
| Completed | 3 | 417 | NA | asenapine, Placebo, olanzapine | Organon and Co | Schizophrenia | 04/06 | 05/06 | | |
NCT00159744: 3-Week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07008) |
|
|
| Completed | 3 | 488 | NA | Asenapine, Org 5222, Olanzapine, Placebo | Organon and Co, Pfizer | Bipolar Disorder | 04/06 | 04/06 | | |
NCT00143182: 9 Week Extension Study of Asenapine and Olanzapine in Treatment of Mania (P07007)(COMPLETED) |
|
|
| Completed | 3 | 504 | NA | Asenapine, Org 5222, Olanzapine | Organon and Co, Pfizer | Bipolar Disorder | 06/06 | 06/06 | | |
NCT00095524: Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder |
|
|
| Completed | 3 | 300 | US, Europe, RoW | Aripiprazole | Otsuka Pharmaceutical Development & Commercialization, Inc., Otsuka America Pharmaceutical | Body Weight Change, Schizophrenia, Schizoaffective Disorder, Psychotic Disorder | 08/06 | 08/06 | | |
| Completed | 3 | 440 | NA | asenapine, Org 5222, SCH 900274, olanzapine, Zyprexa | Organon and Co | Schizophrenia, Schizoaffective Disorder | 09/06 | 10/06 | | |
| Completed | 3 | | US | bifeprunox | Solvay Pharmaceuticals | Schizophrenia | 11/06 | 11/06 | | |
NCT00159783: 40 Week Extension Study Of Asenapine and Olanzapine For Bipolar Disorder (A7501007)(COMPLETED)(P05857) |
|
|
| Completed | 3 | 218 | NA | asenapine, Org 5222, Olanzapine | Organon and Co, Pfizer | Bipolar Disorder | 04/07 | 04/07 | | |
NCT00156091: Long-Term Efficacy and Safety of Asenapine Using Olanzapine as a Positive Control (41512)(COMPLETED)(P05784) |
|
|
| Completed | 3 | 260 | NA | Olanzapine, Asenapine, Placebo | Organon and Co | Schizophrenia | 06/07 | 06/07 | | |
NCT00212836: Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (25543)(COMPLETED)(P05817) |
|
|
| Completed | 3 | 481 | NA | asenapine, olanzapine, Zyprexa | Organon and Co | Schizophrenia | 06/07 | 08/07 | | |
2004-002560-17: A Multicenter, Double-Blind, Flexible-Dose, 6-Month Trial Comparing the Efficacy and Safety of Asenapine With Olanzapine in Stable Subjects With Predominant, Persistent Negative Symptoms of Schizophrenia |
|
|
| Completed | 3 | 444 | Europe, RoW | Asenapine tablets, Zyprexa 5 mg coated tablets, Zyprexa 10 mg coated tablets, Org 5222, Zyprexa 5 mg coated tablets, Zyprexa 10 mg coated tablets, Tablet, Zyprexa 5 mg coated tablets, Zyprexa 10 mg coated tablets | NV Organon, Pfizer Limited, ORGANON ITALIA | Schizophrenia with predominant, persistent negative symptoms | | | | |
NCT00350467: A Randomized, Active-controlled, Double-blind, Parallel-Goup Study of the Efficacy and Safety of Extended Release(ER) Paliperidone in the Treatment of Schizophrenia |
|
|
| Completed | 3 | 288 | RoW | ER OROS paliperidone and Olanzapine | Xian-Janssen Pharmaceutical Ltd. | Acute Schizophrenia | | 09/07 | | |
NCT00380224: Study Comparing the Affect of Bifeprunox Vs Olanzapine on Weight During the Treatment of Outpatients With Schizophrenia. |
|
|
| Completed | 3 | 120 | US | bifeprunox, olanzapine | Wyeth is now a wholly owned subsidiary of Pfizer | Schizophrenia | | 09/07 | | |
NCT00396565: A Study to Evaluate Effectiveness and Safety of ER OROS Paliperidone in Patients With Schizophrenia |
|
|
| Completed | 3 | 394 | Japan | ER OROS paliperidone, Placebo, Olanzapine | Janssen Pharmaceutical K.K. | Schizophrenia | 11/07 | 11/07 | | |
NCT00265343: 6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptom Patients Who Completed the Protocol 25543 (25544)(P05777) |
|
|
| Completed | 3 | 306 | NA | asenapine, olanzapine | Organon and Co | Schizophrenia | 12/07 | 01/08 | | |
| Withdrawn | 3 | 30 | Europe | Olanzapine, EU/1/96/022/002+019 | Charite University, Berlin, Germany, Eli Lilly and Company | Relapse Rate of a Major Depressive Episode, Safety of Olanzapine in Subjects With Major Depression | 01/08 | 04/08 | | |
2005-002169-35: A Multicenter, Double-Blind, Flexible-Dose, 6-Month Extension Trial Comparing the safety and Efficacy of Asenapine With Olanzapine in Subjects who Completed Protocol 25543 |
|
|
| Completed | 3 | 380 | Europe, RoW | Asenapine tablets, Zyprexa 5 mg coated tablets, Zyprexa 10 mg coated tablets, Org 5222, Zyprexa 5 mg coated tablets, Zyprexa 10 mg coated tablets, Tablet, Zyprexa 5 mg coated tablets, Zyprexa 10 mg coated tablets | NV Organon, Pfizer Limited, ORGANON ITALIA, PFIZER | Schizophrenia with predominant, persistent negative symptoms | | | | |
| Completed | 3 | 286 | US, Canada, Europe, RoW | Aripiprazole, Olanzapine, Risperidone, Quetiapine, Ziprasidone | Solvay Pharmaceuticals, H. Lundbeck A/S, Wyeth is now a wholly owned subsidiary of Pfizer | Schizophrenia and Schizoaffective Disorder | 02/08 | 02/08 | | |
| Completed | 3 | 50 | US | Injectable Risperidone (Consta) or oral antipsychotic, Long actiing risperidone injection (Consta), oral risperidone (risperdal)., Olanzapine (Zyprexa), Quetiapine (Seroquel), Ziprasidone (Geodon), Aripiprazole (Ablify) | University of Pittsburgh, Janssen Pharmaceuticals | Bipolar I Disorder | 03/08 | 12/09 | | |
NCT00759421: Exploratory Cognition Study of Sertindole in Patients With Schizophrenia |
|
|
| Completed | 3 | 96 | RoW | Sertindole, Olanzapine, Zyprexa | H. Lundbeck A/S | Schizophrenia | 03/08 | 04/08 | | |
NCT00759460: Study on Metabolic Parameters of Sertindole in Patients With Schizophrenia |
|
|
| Completed | 3 | 250 | RoW | Sertindole, Olanzapine, Zyprexa | H. Lundbeck A/S | Schizophrenia | 03/08 | 04/08 | | |
NCT00864045: Sertindole in Asian Patients With Schizophrenia |
|
|
| Completed | 3 | 394 | RoW | Sertindole, Olanzapine | H. Lundbeck A/S | Schizophrenia | 03/08 | 05/08 | | |
NCT00259272: Validation of Multidimensional Assessment of THYmic States (MATHYS): A Study in a Population of Bipolar Patients Treated With Olanzapine |
|
|
| Completed | 3 | 141 | Europe | olanzapine, LY170053, Velotab, Zydis | Eli Lilly and Company | Bipolar Disorder I or II | 05/08 | 05/08 | | |
NCT00401973: Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With Olanzapine |
|
|
| Completed | 3 | 199 | US, RoW | olanzapine, LY170053, Zyprexa, amantadine, metformin, zonisamide, Wellness education | Eli Lilly and Company | Schizophrenia, Schizoaffective Disorders | 09/08 | 09/08 | | |
NCT00145496: Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (A7501013)(COMPLETED)(P05771) |
|
|
| Completed | 3 | 468 | NA | Asenapine, Olanzapine | Organon and Co | Schizophrenia | 11/08 | 12/08 | | |
NCT00129220: Trial of Olanzapine in Patients With Manic or Mixed Episode of Bipolar I Disorder |
|
|
| Completed | 3 | 224 | Japan | olanzapine, LY170053, Zyprexa, haloperidol, placebo | Eli Lilly and Company | Bipolar Disorder | 01/09 | 01/09 | | |
NCT00438776: Safety and Efficacy Trial of Olanzapine in Outpatients With Pathological Gambling |
|
|
| Completed | 3 | 42 | US | olanzapine, zyprexa, sugar pill, fake pill | Lindner Center of HOPE, Eli Lilly and Company, University of Cincinnati | Pathological Gambling | 03/09 | 03/09 | | |
NCT00174265: 6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptoms Patients Who Completed the First 6- Month Trial (A7501014)(COMPLETED)(P05772) |
|
|
| Completed | 3 | 196 | NA | asenapine, olanzapine, Zyprexa | Organon and Co | Schizophrenia | 04/09 | 05/09 | | |
NCT00266630: Efficacy and Safety of Olanzapine in the Extended Treatment for Manic or Mixed Episode of Bipolar I Disorder |
|
|
| Completed | 3 | 139 | Japan | olanzapine, LY170053, Zyprexa, lithium, valproate, carbamazepine | Eli Lilly and Company | Manic or Mixed Episode Associated With Bipolar I Disorder | 05/09 | 05/09 | | |
| Completed | 3 | 478 | US, Europe, RoW | Lurasidone, Olanzapine, Placebo comparator, Lurasidone 40 mg tablets | Sunovion | Schizophrenia | 12/09 | 01/10 | | |
|
NCT00510146: Olanzapine Treatment of Patients With Bipolar I Disorder |
|
|
| Completed | 3 | 514 | Japan, RoW | Olanzapine, LY170053, Zyprexa, Placebo | Eli Lilly and Company | Depression, Bipolar | 03/10 | 07/10 | | |
NCT00490971: A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Disorder |
|
|
| Completed | 3 | 768 | US, Europe, RoW | Olanzapine, Paliperidone ER, Placebo | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Bipolar Disorder | 04/10 | 04/10 | | |
NCT00618748: Safety and Efficacy of Olanzapine in the Long-term Treatment for Bipolar I Disorder, Depressed |
|
|
| Completed | 3 | 101 | Japan | Olanzapine, LY170053 | Eli Lilly and Company | Bipolar I Disorder | 09/10 | 09/10 | | |
NCT00363376: A Study of Zonisamide to Prevent Olanzapine-Associated Weight Gain |
|
|
| Completed | 3 | 42 | US | zonisamide, Zonegran, olanzapine, Zyprexa, Zydis, Zonisamide, Sugar Pill (placebo) | Lindner Center of HOPE, Eli Lilly and Company, University of Cincinnati | Weight Gain | 02/11 | 02/11 | | |
NCT01977300: Atypical Antipsychotics for Continuation and Maintenance Treatment After an Acute Manic Episode |
|
|
| Completed | 3 | 159 | Canada | Valproate, Valproic Acid, Lithium, Lithium Carbonate, Risperidone, Risperdal, Olanzapine, Zyprexa, Placebo, Sugar Pill | University of British Columbia, Canadian Institutes of Health Research (CIHR), Eli Lilly and Company, Janssen-Ortho Inc., Canada | Bipolar I Disorder | 08/11 | 08/11 | | |
| Withdrawn | 3 | 0 | US | Olanzapine (Zyprexa), Typicals | VA Connecticut Healthcare System, Clinical Trials Network of Columbia U, Cornell U, and NY Presbyterian Hospital, Eli Lilly and Company | Schizophrenia, Schizoaffective Disorder | 06/12 | 06/12 | | |
NCT01617187 / 2010-018407-28: A Study of the Efficacy and Safety of Asenapine in Participants With an Acute Exacerbation of Schizophrenia (P05688) |
|
|
| Completed | 3 | 360 | NA | Asenapine, Placebo Asenapine, Olanzapine, Placebo Olanzapine | Organon and Co | Schizophrenia | 08/14 | 09/14 | | |
| Completed | 3 | 105 | US | Asenapine, Saphris®, SCH 900274, Org 5222, Sycrest®, Placebo Asenapine, Olanzapine, Zyprexa, Placebo Olanzapine | Forest Laboratories | Schizophrenia | 03/15 | 03/15 | | |
| | 3 | 14 | Europe | Pomaglumetad methionil, ABILIFY, ZYPREXA, RISPERDAL, SEROQUEL, LY2140023, 129722-12-9, | Eli Lilly and Company, Lilly S.A., Eli Lilly and Company, , Lilly S.A. | Schizophrenia | | 08/12 | | |
| Completed | 3 | 1098 | Europe, Canada, US, RoW | Risperidone, Olanzapine, Lu AF35700 | H. Lundbeck A/S | Schizophrenia | 08/18 | 10/18 | | |
| Terminated | 3 | 119 | Europe, Japan, US, RoW | Lu AF35700, Risperidone, Olanzapine | H. Lundbeck A/S | Treatment-resistant Schizophrenia | 12/18 | 02/19 | | |
DREaM, NCT02431702: A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform |
|
|
| Completed | 3 | 337 | US, RoW | Aripiprazole, Haloperidol, Olanzapine, Oral Paliperidone ER, Perphenazine, Quetiapine, Oral Risperidone, Paliperidone Palmitate Injection (PP1M), Paliperidone Palmitate Injection (PP3M) | Janssen Scientific Affairs, LLC | Schizophrenia, Psychotic Disorders | 11/19 | 11/19 | | |
OFFER, NCT04536558: Olanzapine Plus Fosaprepitant Standard Antiemetic Therapy in the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients Receiving High Emetic Risk Multi-day Chemotherapy: a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study |
|
|
| Not yet recruiting | 3 | 352 | RoW | olanzapine plus fosaprepitant-based triple regimen, placebo plus fosaprepitant-based triple regimen | Sun Yat-sen University, Jiangsu Hansoh Pharmaceutical Co., Ltd. | Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy | 02/21 | 03/21 | | |
NCT03187769 / 2017-000497-11: Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder |
|
|
| Completed | 3 | 426 | Europe, US, RoW | ALKS 3831, Olanzapine | Alkermes, Inc. | Schizophrenia, Schizophreniform Disorders, Bipolar I Disorder | 12/21 | 01/22 | | |
|
2022-001865-11: A Study to Test if TV-44749 is Effective in Relieving Schizophrenia |
|
|
| Not yet recruiting | 3 | 640 | Europe | Olanzapine, TV44749, Powder and solvent for prolonged-release suspension for injection | Teva Branded Pharmaceutical Products R&D, Inc., Teva Branded Pharmaceutical Products R&D, Inc. | Schizophrenia is a serious mental disorder in which people interpret reality abnormally. It is a severely debilitating psychotic disorder characterized by positive symptoms (eg, delusions, hallucinations, and grossly disorganized behavior) and negative symptoms (eg, affective flattening, alogia, and avolition)., Schizophrenia is a mental disorder that may result in some combination of hallucinations, delusions, and extremely disordered thinking and behavior that impairs daily functioning and can be disabling, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
SOLARIS, NCT05693935: A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With Schizophrenia |
|
|
| Active, not recruiting | 3 | 675 | Europe, US, RoW | TV-44749 - Dose level 1, TV-44749 - Dose level 2, TV-44749 - Dose level 3, Placebo | Teva Branded Pharmaceutical Products R&D, Inc. | Schizophrenia | 03/24 | 01/25 | | |
| Withdrawn | 2/3 | 0 | US | Aripiprazole, Zyprexa, Risperdal | Washington University School of Medicine, Pfizer | Diabetes | 11/09 | 11/09 | | |
| Terminated | 2/3 | 1210 | Japan, US, RoW | LY2140023, mGlu 2/3 Prodrug II, Olanzapine, Zyprexa, LY170053, Aripiprazole, Risperidone, Quetiapine | Eli Lilly and Company | Schizophrenia | 10/12 | 10/12 | | |
2020-006062-36: A Phase II/III, randomized, 4-week, placebo-controlled study, designed to determine the safety, tolerability, and efficacy of evenamide (NW-3509) in patients with chronic schizophrenia. |
|
|
| Ongoing | 2/3 | 196 | Europe, RoW | Evenamide, NW3509, Capsule, hard | Newron Pharmaceuticals S.p.A., NEWRON PHARMACEUTICALS SPA, Newron Pharmaceuticals S.p.A, Newron Pharmaceuticals S.p.A., Newron Pharmaceuticals S.p.A | Chronic schizophrenia, Chronic schizophrenia, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
